JHS Svendgaard Laboratories Completes Warrant Conversion, Allots 18.02 Lakh Equity Shares

JHS Svendgaard Laboratories Limited has completed the conversion of warrants into equity shares, marking a significant milestone in its capital restructuring process. The company's Board of Directors approved the allotment of 18,01,801 equity shares on February 01, 2026, following the successful conversion of an equal number of warrants. Warrant Conversion Details The conversion involved warrants originally issued on August 03, 2024, at an issue price of Rs. 27.75 per warrant. The Board approved the allotment of equity shares with a face value of Rs. 10.00 each at the same issue price of Rs. 27.75, including a premium of Rs. 17.75 per share. Parameter: Details Total Warrants Converted: 18,01,801 Issue Price per Share: Rs. 27.75 Face Value per Share: Rs. 10.00 Premium per Share: Rs. 17.75 Total Amount Received: Rs. 3,74,99,983.31 Allottee Information Coeus Global Opportunities Fund was the sole beneficiary of this warrant conversion, receiving the entire allocation of 18,01,801 equity shares. The fund paid the balance amount of Rs. 3,74,99,983.31, representing 75% of the total issue price, as required under SEBI regulations. Allottee Details: Information Allottee Name: Coeus Global Opportunities Fund Warrants Held: 18,01,801 Shares Allotted: 18,01,801 Post-Allotment Shareholding: 2.06% Pending Warrants: 0 Impact on Share Capital Following this allotment, JHS Svendgaard Laboratories' paid-up equity share capital has increased to Rs. 87,40,57,670, now comprising 8,74,05,767 equity shares of Rs. 10.00 face value each. The newly issued shares carry the same rights and privileges as existing equity shares of the company. Regulatory Compliance The warrant conversion was conducted in accordance with SEBI (ICDR) Regulations, 2018, and the company has fulfilled all disclosure requirements under Regulation 30 of SEBI Listing Regulations. The Board meeting, which commenced at 10:00 A.M. and concluded at 10:23 A.M., ensured all procedural requirements were met for this preferential allotment on a private placement basis. JHS Svendgaard Laboratories Limited , a company listed on Indian stock exchanges, has taken a significant step towards employee engagement and retention. The company's Nomination and Remuneration Committee has approved the grant of 31,30,000 employee stock options (ESOPs) under its newly introduced Employee Stock Option Scheme-2025. Key Details of the ESOP Grant Particulars Details Scheme Name JHS Svendgaard Laboratories Limited Employee Stock Option Scheme – 2025 Number of Options Granted 31,30,000 Face Value of Shares Rs. 10 each Exercise Price Rs. 10 per option Effective Grant Date November 14, 2025 Vesting and Exercise Details The approved ESOP scheme includes the following vesting and exercise provisions: Vesting Period: Commences one year from the grant date and extends up to five years Exercise Period: Maximum of 5 years from the respective vesting date Special Provisions: In case of death or permanent disability of a grantee, the minimum one-year vesting period is waived Compliance and Regulatory Aspects The company has confirmed that the ESOP scheme is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. This grant of ESOPs was disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Implications for Employees and Shareholders The introduction of this ESOP scheme represents a strategic move by JHS Svendgaard Laboratories to align employee interests with those of the company and its shareholders. By offering equity participation, the company aims to motivate and retain key talent, potentially leading to improved performance and long-term value creation. For existing shareholders, while there may be a potential dilution effect in the future when these options are exercised, the alignment of employee interests with company performance could potentially offset this through improved corporate results. As the vesting period extends over several years, the full impact of this ESOP grant on the company's financial statements and share structure will unfold gradually. Investors and stakeholders may want to monitor future financial reports for updates on the scheme's implementation and its effects on the company's performance and equity structure. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.